Literature DB >> 18613128

Application of computer to monitoring and control of fermentation process: Microbial conversion of ML-236B Na to pravastatin.

M Hosobuchi1, K Kurosawa, H Yoshikawa.   

Abstract

An automatic feeding process for microbial hydroxylation of ML236B sodium salt (ML-236B Na; compactin) by Streptomyces carbophilus SANK 62585 was developed. The hydroxylated product, pravastatin sodium salt (pravastatin; trade name Mevalotin), is an inhibitor of 3-hydroxy-3-methyglutaryl-coenzyme A reductase (HMG-CoA reductase) used as cholesterol-lowering drug. The hydroxylation activity of S. carbophilus was induced by the addition of ML236B Na to culture broth but inhibited by high concentration of ML236B Na. In order to obtain high conversion yield, it was necessary to maintain optimum ML236B Na concentration throughout the fermentation by continuous feeding. For this purpose, we developed an on-line monitoring method, which mainly consisted of a cross-flow filtration module, high-performance liquid chromatography (HPLC) analyzer, feed pump, and microcomputer for regulation of ML236B Na concentration. An algorithm for control of ML236B Na feed rate based on feedback and feed-forward control where conversion rate after Deltat was estimated by using regression analysis of the five latest values of conversion rate. In a fed-batch culture employing this system, the concentration of ML236B Na was maintained at optimum level during the fermentation and the productivity of pravastatin was increased threefold over that obtained in manual control culture. (c) 1993 John Wiley & Sons, Inc.

Entities:  

Year:  1993        PMID: 18613128     DOI: 10.1002/bit.260420705

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  5 in total

1.  Screening of compactin-resistant microorganisms capable of converting compactin to pravastatin.

Authors:  Chao-Hsien Chen; Hui-Yu Hu; Yen-Ching Cho; Wen-Hwei Hsu
Journal:  Curr Microbiol       Date:  2006-06-26       Impact factor: 2.188

2.  Bioconversion of FR901459, a novel derivative of cyclosporin A, by Lentzea sp. 7887.

Authors:  Satoshi Sasamura; Motoo Kobayashi; Hideyuki Muramatsu; Seiji Yoshimura; Takayoshi Kinoshita; Hidenori Ohki; Kazuki Okada; Yoko Deai; Yukiko Yamagishi; Michizane Hashimoto
Journal:  J Antibiot (Tokyo)       Date:  2015-03-18       Impact factor: 2.649

Review 3.  Engineering cytochrome P450 enzyme systems for biomedical and biotechnological applications.

Authors:  Zhong Li; Yuanyuan Jiang; F Peter Guengerich; Li Ma; Shengying Li; Wei Zhang
Journal:  J Biol Chem       Date:  2019-12-06       Impact factor: 5.157

4.  Single-step fermentative production of the cholesterol-lowering drug pravastatin via reprogramming of Penicillium chrysogenum.

Authors:  Kirsty J McLean; Marcus Hans; Ben Meijrink; Wibo B van Scheppingen; Aad Vollebregt; Kang Lan Tee; Jan-Metske van der Laan; David Leys; Andrew W Munro; Marco A van den Berg
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-17       Impact factor: 11.205

Review 5.  Rational and semi-rational engineering of cytochrome P450s for biotechnological applications.

Authors:  Lian-Hua Xu; Yi-Ling Du
Journal:  Synth Syst Biotechnol       Date:  2018-10-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.